GOODWILL AND OTHER INTANGIBLE ASSETS

6 Months Ended

Jun. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

GOODWILL AND OTHER INTANGIBLE ASSETS

Dollars in Millions	Estimated Useful Lives	June 30, 2020		December 31, 2019
Goodwill(a)		$	20,578	$	22,488
Other intangible assets:
Licenses	5 – 15 years	461		482
Acquired developed product rights(a)	3 – 15 years	57,852		46,827
Capitalized software	3 – 10 years	1,296		1,297
IPRD		8,400		19,500
Gross other intangible assets		68,009		68,106
Less accumulated amortization		(8,838)		(4,137)
Other intangible assets		$	59,171	$	63,969

(a) Includes measurement period adjustments. Refer to “—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements” for more information.

In the six months ended June 30, 2020, $11.1 billion of IPRD was reclassified to acquired developed product rights upon approval in the U.S. for Reblozyl for the treatment of anemia in adults with lower-risk MDS and Zeposia. Amortization expense of other intangible assets was $2.5 billion and $4.8 billion for the three and six months ended June 30, 2020 and $51 million and $104 million for the three and six months ended June 30, 2019, respectively.